ENDP Stock Recent News

Endo International plc's (NASDAQ: ENDP) Q1 sales decreased 9% to $652.26 million, beating the consensus of $633.41 million. The decrease was attributable to decreased revenues from the sterile injectables segment, partially offset by increased revenues from the generic segment and.

The company provided disappointing Q2 guidance.

Endo International plc (NASDAQ:ENDP ) Q1 2022 Earnings Conference Call May 6, 2022 7:30 AM ET Company Participants Laure Park - Senior Vice President, Investor Relations and Corporate Affairs Blaise Coleman - President and Chief Executive Officer Mark Bradley - Executive right Vice President and Chief Financial Officer Patrick Barry - President, Global Commercial Operations Conference Call Participants Chris Schott - JPMorgan David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Nathan Rich - Goldman Sachs Operator Good day and welcome to the First Quarter 2022 Endo International Plc Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

Endo International PLC (NASDAQ: ENDP) shares are trading lower by 34.65% at $1.32 after the company reported first-quarter earnings results and issued second-quarter guidance. Endo International reported quarterly earnings of 66 cents per share which beat the analyst consensus.

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.